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he Coalition against Typhoid (CaT): addressing barriers to
yphoid vaccine implementation
. Nelson ∗, C. de Quadros
Sabin Vaccine Institute, Washington, DC, USA
Background: Typhoid fever continues to be a major public
ealth problem. In endemic communities and during outbreaks,
nfants, toddlers and young children are disproportionately
ffected.WHOestimates 21million cases and216,000deaths occur,
nnually.Whileoutbreak reports are common, estimatesof typhoid
urden have been limited by the absence of standardized surveil-
ance, especially in sub-Saharan Africa.
Methods: Effective case management can reduce case-fatality
ates. However, widespread and increasing prevalence of mul-
idrug (MDR) resistance and nalidixic-acid-resistance (NAR) have
educedeffective treatmentoptions, increased costs and resulted in
igher ratesof seriouscomplicationsanddeaths. Ingeneral, surveil-
ance and case management is limited by the poor performance of
yphoid diagnostics. Typhoid vaccines – oral live attenuated Ty21a
nd injectable Vi polysaccharide – are safe and efﬁcacious. In 2011,
HO granted prequaliﬁcation to a Vi polysaccharide vaccine.
Results: The programmatic use of typhoid vaccines is a global
ealth priority supported by WHO and prioritized by the GAVI
lliance. WHO SEARO has prioritized typhoid vaccines for immedi-
te introduction and the Indian Academy of Pediatrics recommends
he use of ViPS vaccines in children 2-15y. Despite this, the imple-
entation of typhoid vaccines as part of national or municipal
mmunization programs has been slow.
The Coalition against Typhoid (CaT) was established in 2009 to
ddress the barriers to typhoid vaccine adoption. These include:
imited local surveillance and poor diagnostics; low awareness
f the widespread and increasing prevalence of MDR and NAR
yphoid; and low awareness of the successful use of vaccines to
ontrol disease.
Conclusion: Typhoid vaccines are inexpensive, vaccination
trategies are cost-effective, and there is high demand for vaccine
n affected populations. Recognizing the need for vaccines that are
afe and effective in infants/young populations and that provide
ong lasting and high levels of protection, typhoid conjugate vac-
ines are currently in clinical development, with some focused on
ffering combined protection against S. Typhi and S. Paratyphi. The
ontrol of enteric fever caused by S. Typhi is a global health prior-
ty. Safe, effective and affordable vaccines can be used as part of
comprehensive and integrated strategy to control typhoid fever.
ww.COALITIONagainstTYPHOID.org
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Production of tissue culture rabies vaccine for human use in
Nepal
G.R. Pant
Rabies Vaccine Production Laboratory, Kathmandu, Nepal
Background: A trail batch of tissue culture inactivated anti
rabies vaccine was produced at Rabies Vaccine production Labora-
tory in Kathmandu in 2010 by using Vero cell. The potency (IU/ml)
of this vaccinewas 4.6when tested inNancyWild Life Laboratory in
France. The result of other quality test such as inactivation, toxicity,
safety, speciﬁcity, sterility and pH test were found satisfactory.
Methods: Vero working cell line (164P) was used for propa-
gation of cell that was infected with PV/RV at 100 MOI working
rabies virus strain at 170 serial passages of cells. Virus cultures
ﬂuid was harvested and pooled sample of ﬂuid was tested by using
Anigen Rapid Test Kit for the detection of rabies virus. Pooled sam-
ple was found positive for rabies virus antigen where as the ﬂuid
collected from control cell was negative for rabies virus. The har-
vested viruswas then centrifuged at 10,000 rpm and condensed for
puriﬁcation in pellicon machine (milli pore) under Pump Master
ﬂex speed 0.5, feed pressure 0.2 Kg/cm2 and pellicon ﬁlter mem-
brane 0.02 um pore size. The titer of virus before inactivation was
10 7.5 TCID 50/0.1ml. Finally this virus ﬂuid was inactivated with
beta propiolactone
Results: The titer of virus before inactivation was 10 7.5 TCID
50/0.1ml. Finally this virus ﬂuid was inactivated with beta propio-
lactone. The ED 50 of the titer of vaccine was 10 when challenged
with CVS 50 LD50 /0.03ml in NIH test. The potency (IU/ml) of
this vaccine was 4.6 when tested in Nancy Wild Life Laboratory in
France. The result of other quality test such as inactivation, toxicity,
safety, speciﬁcity, sterility and pH test were found satisfactory.
Conclusion: Vaccine is satisfactory for human use.
http://dx.doi.org/10.1016/j.ijid.2012.05.1007
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ModeofAction (MoA) studies contribute to the safetyevaluation
of AS04 adjuvanted vaccines
S. Preiss, M. Mergaerts, A. Di Pasquale ∗, N. Garcon
GlaxoSmithKline Biologicals, Wavre, Belgium
Background:By incorporating novel adjuvants into vaccine for-
mulationswe aim to enhance and guide immune responses elicited
against the vaccine antigen. Vaccines undergo a continuous and
rigorous safety assessmentduringdevelopmentandafter licensure.
Increased knowledge regarding the safety of adjuvanted vac-
cines, collected from the adjuvant’s mode of action (MoA)
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nvestigations and pre-clinical and clinical safety studies, may help
o make informed decisions in clinical practice.
Methods: Pre-clinical toxicology and clinical safety assess-
ents, both within the context of controlled clinical trials and
ost-marketing surveillance, are conducted for all licensed vac-
ines. In addition pre-clinical adjuvant MoA studies provide
dditional information regarding the safety proﬁle of novel adju-
anted vaccines. Our discussion will focus on the added support
hat MoA studies bring to the safety evaluation of adjuvanted vac-
ines. As an example of MoA and safety data we will use the results
f studies with the AS04-adjuvanted L1/16&18 HPV vaccine.
Results: The preclinical toxicology package of the AS04-
djuvanted L1/16&18 HPV vaccine has not shown treatment-
elated toxicologyﬁndings other than local injection site inﬂamma-
ion. MoA data showed that AS04 induced a transient and localised
ctivation of innate cells at the injection site and in the local drain-
ng lymph nodes, with no systemic impact or direct effect on T
ells and B-cellls. Clinical safety evaluation and follow-up in a trial
etting have shown no clinically relevant differences compared
ith control groups other than reactogenicity, mostly at local level,
onsistent with ﬁndings from preclinical data and MoA studies.
inally, with more than 25 million doses distributed worldwide,
ost-licensure safety evaluations have shown adverse events con-
istent with what has been observed in the clinical development
rogram, with most commonly reported events being local site
eactions of short duration (2-3 days).
Conclusion:Regulatory authorities require rigorouspre-clinical
nd clinical safety data to determine the beneﬁt/risk proﬁle of new
accines. Post-licensure, a continuous pharmacovigilance system
s in place to further assess vaccine safety. Research studying the
echanism of action of an adjuvanted vaccine can help to further
nvestigate the vaccine’s safety proﬁle.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.1008
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uberculin skin test andBCGscar in childrenvaccinatedatbirth:
study from Iran
. raﬁei tabatabaei1,∗, F. Shiva2, H. Mohebati3, H. Behbod3, A.
arimi1
Pediatric infectious Research disease, Tehran, Iran, Islamic Republic
f
Pediatric Infections Research Center, Shaheed Beheshti University of
edical Sciences, Tehran, Iran, Tehran, Iran, Islamic Republic of
Pediatric Infectious Research Center, Shaheed Beheshti University,
ehran, IRAN, Tehran, Iran, Islamic Republic of
Background: The rates of positive tuberculin skin test reactions
nd BCG scarring after BCG vaccination vary between studies and
opulations. Tuberculin reactivity and BCG scarring may be related
o better child survival in low-income countries.
This studywasperformedtoassess the reaction to the tuberculin
kin test and the development of the BCG scar in a cohort of healthy
ewborns.
Methods: We performed the tuberculin test with Puriﬁed pro-
ein derivative (PPD) and the BCG scar in 794 infants 3months after
accination at birth in Arak, Iran.fectious Diseases 16S (2012) e158–e316
Results: Of all children 413 were female (52%). Response to
the tuberculin test was negative in 39%, doubtful in 55% and posi-
tive in 6%. In 96% of cases B.C.G scar was ≥3mm in diameter. The
average size of the reaction to PPD in those with a BCG scar was
greater than those without a scar in all the children in our study,
(p-value <0.001).
Conclusion: In the present study about 96% of infants had a
successful response to BCG vaccination while 4% did not develop a
scar. In some countries repeat vaccination is universal; in others it
is based on either tuberculin skin testing or the absence of a typical
scar. Since the absence of development of the scar does not always
signify a lack of response to the BCG, therefore it is better to do fur-
ther immunological tests to detect a reaction to the vaccine before
deciding to revaccinate these children.
http://dx.doi.org/10.1016/j.ijid.2012.05.1009
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The effect of propolis ethanol extract on humoral and cellu-
lar responses ofmice immunizedwith Leishmania recombinant
GP63 protein
M. Rasouli1,∗, M. Keshavarz2, M. Kalani3, S. Asaei1
1 Shiraz University of Medical Sciences-Clinical Microbiology Research
Center, Shiraz, Iran, Islamic Republic of
2 Shiraz University of Medical Sciences-Clinical Microbiology Research
center, Shiraz, Iran, Islamic Republic of
3 Shiraz University of Medical Sciences-Clinical Microbiology research
Center„ Shiraz, Iran, Islamic Republic of
Background: Propolis is a natural resinous hive product, col-
lected by honey bees from plants and mixes with their wax.
Regarding to its pharmacological activities and adjuvants prop-
erty in vaccine formulations, the effect of propolis extracts on
the humoral and cellular immune responses can be exploited for
the development of effective vaccines. This work evaluated the
adjuvant capacity of an ethanol extract of propolis associated to
recombinant GP63 Leishmania protein.
Methods: Brieﬂy, the propoliswas ground andmacerated for 10
days with an extract solution containing absolute ethanol. Then,
the solvent was evaporated and the resulting dried matter was
dissolved in PBS. 27 male BALB/c mice, allocated into four groups,
were inoculated subcutaneously with 0.1ml of 4 different vaccines
formulates at day 0, 7 and 30. Group 1 to 4 have been injected
with normal saline, 50g recombinant (r) GP63, 50g rGP63 plus
5mgpropolis, and 5mgpropolis, respectively. 30 days after the last
inoculation, splenic mononuclear cells were obtained from spleens
of treated mice by Ficol hypaque gradient and 107 isolated cells
were resuspended in 1ml media supplemented with 10% of bovine
fetal serum. The105 cells plated in a 96 well plate and treated with
rGP63. After 4 days, the supernatant was assayed for the content of
IL-4 and IFN- by ELISA methods.
Results: The level of the IL-4 in the Propolis plus rGP63
group was signiﬁcantly higher than the control and rGP63 groups
(P =0.002, P =0.001, respectively). Based on the level of IFN-, no
signiﬁcant differences were observed between propolis plus rGP63
and other treated group.
